Canalevia ® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs Jaguar is exploring the ...
Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S. Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN ...
Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare CDD, in the US, EU, ...
[{"search_type":"general-inventory-search","vehicle_array":[{"trim":"110 P400 X-Dynamic SE","make":"Land Rover","cat":"luxurysuv_crossover","year":"2025","customer_id ...
Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome (SBS) and microvillus inclusion disease (MVID), an ultrarare ...
Canalevia ® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs Jaguar is exploring the ...
New patent issued for core rare disease target indication for crofelemer Jaguar has approximately 200 patents issued and pending Jaguar is supporting investigator-initiated proof-of-concept studies of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback